12 research outputs found

    The CHEOPS mission

    Full text link
    The CHaracterising ExOPlanet Satellite (CHEOPS) was selected in 2012, as the first small mission in the ESA Science Programme and successfully launched in December 2019. CHEOPS is a partnership between ESA and Switzerland with important contributions by ten additional ESA Member States. CHEOPS is the first mission dedicated to search for transits of exoplanets using ultrahigh precision photometry on bright stars already known to host planets. As a follow-up mission, CHEOPS is mainly dedicated to improving, whenever possible, existing radii measurements or provide first accurate measurements for a subset of those planets for which the mass has already been estimated from ground-based spectroscopic surveys and to following phase curves. CHEOPS will provide prime targets for future spectroscopic atmospheric characterisation. Requirements on the photometric precision and stability have been derived for stars with magnitudes ranging from 6 to 12 in the V band. In particular, CHEOPS shall be able to detect Earth-size planets transiting G5 dwarf stars in the magnitude range between 6 and 9 by achieving a photometric precision of 20 ppm in 6 hours of integration. For K stars in the magnitude range between 9 and 12, CHEOPS shall be able to detect transiting Neptune-size planets achieving a photometric precision of 85 ppm in 3 hours of integration. This is achieved by using a single, frame-transfer, back-illuminated CCD detector at the focal plane assembly of a 33.5 cm diameter telescope. The 280 kg spacecraft has a pointing accuracy of about 1 arcsec rms and orbits on a sun-synchronous dusk-dawn orbit at 700 km altitude. The nominal mission lifetime is 3.5 years. During this period, 20% of the observing time is available to the community through a yearly call and a discretionary time programme managed by ESA.Comment: Submitted to Experimental Astronom

    RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients

    Get PDF
    Rheumatoid arthritis (RA) is a chronic inflammatory disorder with poorly defined aetiology characterised by synovial inflammation with variable disease severity and drug responsiveness. To investigate the peripheral blood immune cell landscape of early, drug naive RA, we performed comprehensive clinical and molecular profiling of 267 RA patients and 52 healthy vaccine recipients for up to 18 months to establish a high quality sample biobank including plasma, serum, peripheral blood cells, urine, genomic DNA, RNA from whole blood, lymphocyte and monocyte subsets. We have performed extensive multi-omic immune phenotyping, including genomic, metabolomic, proteomic, transcriptomic and autoantibody profiling. We anticipate that these detailed clinical and molecular data will serve as a fundamental resource offering insights into immune-mediated disease pathogenesis, progression and therapeutic response, ultimately contributing to the development and application of targeted therapies for RA.</p

    The finite element method as applied to the diffraction by an anisotropic grating

    No full text
    International audienc

    0131: Strategy of anticoagulation in pacemaker and ICD replacement procedure in real life. The French Electra survey

    Get PDF
    Aimto evaluate routine French implanters strategy in device replacement in patients under anticoagulation for atrial Fibrillation (AF pts).MethodA questionnaire was e-mailed to 140 French implanters.Results102 aswers were obtained. In AF patients, admission is on day of procedure D0 (10%) or D-1(80%) whether pts are on vitamine K antagonist(VKA) or New Oral AntiCoagulant (NOAC). In AF pts under VKA, only 4%bridge to Low Weight Heparine (LWH) or Unfractionated Heparine (UH) while treatment is interrupted without substitution (wos) by 61% and continued without interruption by 32%. In AF pts under NOAC, only 5%bridge to UH or LWH while treatment is interrupted on D-3 (13%), D-2(25%), D-1(44%). When interrupted, NOAC are resumed at D0 (23%), D+1(54%), D+2(10%), D+3(3%).ConclusionsMost of implanters hospitalize AF pts at D-1 of replacement procedure. Short discontinuation (VKA, NOAC) or uninterruption (VKA) is prefered to bridging strategy
    corecore